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1. Introduction 
Natural products are a rich source of chemical diversity by 
constantly bringing new skeletons to light. This is highly 
demanded for the development of new drugs and particularly for 
antibacterial compounds due to worldwide emergence of 
multidrug resistance. The development of resistance to classic 
antibiotics has emerged from antibiotic use for both veterinary 
medicine and human medicine. This reduces the effectiveness of 
current treatments for infections and becomes a major threat for 
public health causing a large number of sick people, 
hospitalizations and deaths.1 Because of that, new antibacterial 
molecules are actively sought and this encourages us to devote 
our research efforts to find new active agents.
2
 
Marine butenolides of the cadiolide family, isolated from 
ascidians or tunicates, have shown wide spectrum antibacterial 
activities.
3
 They are characterized by a tris-aromatic furanone 
skeleton, where aryl groups are phenols bearing usually one or 
two bromine atoms. Simpler related bis-aromatic furanones have 




Some members of the cadiolide family, and especially 
cadiolide E, have shown potent inhibition of Candida albicans 
isocitrate lyase activity.
3d
 However, the structure activity 
relationship of these natural compounds has not yet been 
established and may be function of the number and position of 
bromine atoms on the phenolic rings. We recently developed a 
one pot multicomponent procedure
5
 for the preparation of 
substituted acylfuranones by condensation of a hydroxyketone 1, 
a functionalized dioxinone 2 and an aldehyde 3 or a ketone and 
now report on the application of this methodology to the 
synthesis of various cadiolide analogues
5d,e 
and their antibacterial 
activities. The versatility of this method allowed us to easily vary 
the number and position of bromine atoms on the different 
aromatic rings by preparing different brominated substrates 1, 2 
and 3 (Scheme 1). 
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The one-pot multicomponent synthesis of natural butenolides named cadiolides A, B, C and 
analogues has been realized. The antibacterial structure activity relationship shows that the 
presence of phenolic hydroxyl groups and the number and position of bromine atoms on the 
different aromatic rings are important features for antibacterial activity, besides it was 
demonstrated the tolerance of both benzene and furan ring at position 3 of the butenolide 
nucleus. Furthermore, none of the most relevant antibacterial compounds showed any 
cytotoxicity in freshly isolated human neutrophils. 







natural products  
  
 
Figure 1. General structures of cadiolides and rubrolides 
  
 
Scheme 1: Approach to cadiolide analogues 
 
Different aromatic substrates (Figure 2) have then been 
prepared by mono bromination of the pOMe- or dibromination of 
pOH-substituted aromatic ring using conventional methods.6a 
Hydroxyketones 1a-1c have been prepared by bromination of the 
corresponding acetophenone followed by treatment with sodium 
formate.
6b
 Dioxinones 2a-d have been synthesized from the 
corresponding β-ketoesters using our described procedure.5 
Aldehyde 3a-b are commercially available and 3c has been 
prepared by bromination of pOH-benzaldehyde. Heteroaromatic 
dioxinone 2d has also been used in order to determine whether 
non phenolic substituents were tolerated for biological activity. 
 
Figure 2: Set of hydroxyketones, dioxinones and aldehydes 
 
Various methoxy-furanones 4 were then prepared by reaction 
of hydroxyketone 1a-c with dioxinone 2a-d and aldehyde 3a-c at 
150°C under microwave irradiation (5 min), in the presence of 
triethylamine and molecular sieves. Crude reaction mixtures were 
then subsequently demethylated with BBr3 to free the phenols 
and give furanones 5-10. Yields of 4 usually ranged from 40 to 
70% and debromination gave usually good yields of phenols 5-10 
(Scheme 2, Table 1). Among them, three natural products were 
prepared: cadiolide A (7i), cadiolide B (7g) and cadiolide C (6f). 
 
 
Scheme 2: Multicomponent reaction 
  
2. Bactericidal activity.  
A total of 16 substituted furanones 5-10, including the three 
natural cadiolides A, B and C, and 14 methoxy-furanones 4 were 
screened in vitro for their antibacterial activity against several 
human pathogenic bacteria by determination of their minimum 
inhibitory concentrations (MICs, the lowest concentration of 
compounds capable of inhibiting the growth of bacteria) and 
using the 2-fold microtiter method (Table 1, Figure 3).7 
Compounds were evaluated against four Gram-positive bacterial 
strains (Bacillus cereus, Bacillus subtilis, Staphylococcus aureus 
and Enterococcus faecalis) and four Gram-negative (Salmonella 
typhi, Escherichia coli 100, E. coli 405 and Erwinia carotovora). 
Interestingly, compounds in which the unsaturated butenolide 
ring is bearing phenolic hydroxyl groups (furanones 5-10) 
displayed moderate to significant antibacterial activity against 
both Gram-positive and Gram-negative strains tested, whereas 
their methoxy-furanone analogues 4 were completely inactive at 
the highest concentration tested (125 µg/mL, results not shown). 
Therefore, the presence of phenolic hydroxyl groups is crucial for 
antibacterial activity, probably due to their ability to interact with 
proteins and bacterial cell walls to form complexes.
8
 The 
importance of ionizable phenolic hydroxyl groups to enhance 
bactericidal activity has been earlier reported.
9
 It seems that the 
phenolic protons can be replaced by another ion (potassium ion 
or other cation) causing an efflux of cations and influx of protons 
to the cytoplasm. 
 
Figure 3: Synthesis of various butenolides 5-10 
 
Among phenolic analogues, the most potent compounds were 
the synthetic brominated tris-aromatic furanones 6c, 7c and 9, 
with a MIC value of 1.95 µg/mL against the following strains 
tested: B. cereus, S. aureus, E. faecalis, S. typhi and E. coli 405 
(Figure 3, Table 1). The structure-activity relationship (SAR) 
studies highlighted the importance of both number and location 
of bromine atoms. Therefore, our initial studies focused on 
cadiolide analogues bearing a benzoyl substituent attached to 
position 3 of furanone core showed that 5a analogue devoid of 
any bromine atom displayed moderate to low activity (MIC from 
62.5 to 125 µg/mL). In addition, antibacterial activity 
dramatically decreased when a single bromine was added on the 
benzylidene substituent attached to position 5 (compound 5b). 
Low activity was also displayed for compound 5c, with only two 
bromine atoms located on benzylidene and benzoyl substituents. 
However, the antibacterial activity was increased when the two 
  
bromine atoms were located one on the benzylidene and one on 
the phenyl ring, as compound 6b with MICs ranging from 15.62 
to 31.25 µg/mL for B. cereus, S. aureus, E. faecalis, S. typhi and 
E. coli 405. However, adding a third bromine atom led to one of 
the most potent compounds 6c when a bromine atom was located 
on each aryl ring. Cadiolide analogues with four bromine atoms 
resulted in two possible groups of compounds depending on the 
location of bromine atoms on the aryl rings. The first group had 
two bromine atoms in one of the aryl rings and a single bromine 
on each of the other two aryl rings as it occurs for 6e, 6f 
(cadiolide C) and 7c. Results showed that when the two bromine 
atoms were on phenyl or benzylidene substituent (6e and 7), 
higher potency was obtained than when two bromines were on 
the benzoyl substituent (6f, cadiolide C). The second group had 
two bromine atoms on two aryl rings but the third aryl ring did 
not have any bromine, like in compounds 5d, 7i (cadiolide A) 
and 7h. Although the activity of this second group of compounds 
slightly decreased, they followed the same trend, since 7h and 7i 
(cadiolide A) with the two bromine atoms on phenyl or 
benzylidene substituent displayed higher potency than on 
benzoyl substituent (5d). A high antibacterial activity was also 
obtained when a fifth bromine atom was added to yield 
compound 7e, with MICs ranging from 1.95 to 3.90 µg/mL. 
However, the antibacterial activity slightly decreased when a 
sixth bromine was added to give natural product 7g (cadiolide B) 
(MICs ranging from 7.81 to 15.62 µg/mL), even though two 
bromine atoms were located on both benzylidene and phenyl 
substituents.  
In order to improve the antibacterial activity we replaced the 
benzoyl with furoyl substituent to obtain compounds 8-10. SAR 
studies showed that surprisingly compound 8 without any 
bromine, displayed higher activity than its benzoyl analogue 5a. 
The activity increased again when two bromine atoms were 
added as one on the benzylidene and one on the phenyl ring 
(compare 9 versus 6b).  In addition, the presence of a third 
bromine did not seem to affect the activity since compound 10 
displayed the same MIC values than compound 9, which were 
one of the most potent compounds of this series. Therefore, the 
replacement of benzoyl by furoyl moiety proved to be 
advantageous for antibacterial activity in cadiolide analogues. 
 
Table 1. Antibacterial activities. 
MIC (µg.mL-1) 24 ha 
Furanone 5-10 B. cereus S. aureus E. faecalis S. typhi E. coli 405 E. carotovora B. subtilis E. coli 100 
5a 62.5 62.5 125.0 125.0 62.5 125.0 > 125.0 62.5 
5b 125.0 > 125 > 125 > 125 > 125 > 125 > 125 > 125 
5c 3.90 > 125.0 > 125.0 125 125 > 125 > 125 > 125 
5d 15.62 15.62 15.62 15.62 15.62 125.0 125.0 > 125 
6b 15.62 31.25 31.25 31.25 15.62 125 125 15.62 
6cb 1.95 1.95 1.95 1.95 1.95 125.0 125.0 > 125 
6e 1.95 3.90 1.95 3.90 3.90 125.0 125.0 > 125 
6f 
(cadiolide C) 
3.90 3.90 3.90 3.90 3.90 125.0 125.0 > 125 
7cb 1.95 1.95 1.95 1.95 1.95 125.0 125.0 > 125 
7e 3.90 3.90 3.90 3.90 1.95 125.0 125.0 > 125 
7g 
(cadiolide B) 
7.81 7.81 7.81 15.62 7.81 > 125 > 125 > 125 
7h 3.90 3.90 3.90 3.90 7.81 125.0 125.0 > 125 
7i 
(cadiolide A) 
7.81 7.81 7.81 7.81 7.81 125.0 125.0 > 125 
8 15.62 15.62 31.25 15.62 31.25 > 125 > 125 31.25 
9b 1.95 1.95 1.95 1.95 1.95 125.0 125.0 15.62 
10b 3.90 1.95 1.95 1.95 3.90 125.0 125.0 15.62 
tetracycline 3.90 0.24 0.48 7.81 7.81 3.90 0.97 3.90 
a Doses tested were 125, 62.5, 31.25, 15.62, 7.81, 3.9, 1.95, 0.97, 0.48 and 0.24 µg/mL. Gram-positive: Bacillus cereus (CECT 148), 
Staphylococcus aureus (CECT 86), Enterococcus faecalis (CECT 481) and Bacillus subtilis (CECT 35); and four Gram-negative: 
Salmonella typhi (CECT 409), Escherichia coli 100 (CECT 100), E. coli 405 (CECT 405), and Erwinia carotovora (CECT 225); b For 6c, 
IC50= 1.95 µg/mL = 3.06 µM; IC50= 125 µg/mL = 196.21 µM; For 7c, IC50= 1.95 µg/mL = 2.72 µM; IC50= 125 µg/mL = 174.59 µM; For 9, 
IC50= 1.95 µg/mL = 3.66 µM; IC50= 15.62 µg/mL = 29.35 µM; IC50= 125 µg/mL = 234.90 µM; For 10, IC50= 1.95 µg/mL = 3.19 µM; IC50= 
3.90 µg/mL = 6.38 µM; IC50= 15.62 µg/mL = 25.56 µM; IC50= 125 µg/mL = 204.57 µM. 
 
In comparison with tetracycline, it was noteworthy that eight 
of the butenolides tested including cadiolide C were able to 
inhibit the bacterial growth against B. cereus, S. typhi and E. coli 
405 with MIC values lower or in the same order than the 
reference antibiotic. For instance: 6c, 7c and 9 with MIC of 1.95 
µg/mL, 6e, 7e and 10 with MICs ranging from 1.95 to 3.90 
µg/mL, 6f (cadiolide C) with MIC of 3.90 µg/mL, and 7h with 
MICs ranging from 3.90 to 7.81 µg/mL. Compound 7i (cadiolide 
A) required the same concentration than tetracycline to inhibit the 
bacterial growth of S. typhi and E. coli 405 with MIC of 7.81 
  
µg/mL. Full dibrominated 7g (cadiolide B) showed the same 
potency than tetracycline only against E. coli 405 (MIC of 7.81 
µg/mL), and 5d, 6b and 8 exhibited a moderate antibacterial 
activity with MIC against B. cereus, S. aureus, E. faecalis, S. 
typhi and E. coli 405 ranging from 15.62 to 31.25 µg/mL. 
Curiously, among all the tested compounds, only 5a, 6b and the 
furan analogues 8, 9 and 10 displayed significant activity against 
E. coli 100 with MIC values ranging from 15.62 to 62.5 µg/mL. 
In general, the presence of free phenolic groups as unique 
substituents more than bromine atoms on the benzene rings 
attached to positions 4 and 5 seems to favor the activity against 
this bacterium.  
Some compounds were active against both bacterial strains B. 
subtilis (Gram-positive) and E. carotovora (Gram-negative) at 
125 µg/mL, for instance the partially bromineated derivatives 
such as 6c, 6f (cadiolide C), 5d, 7i (cadiolide A), 7h, 7c, 6e, 7e, 
6b and the furan analogues 9 and 10. Among all tested 
compounds, the less active was 5b which was able to inhibit the 
bacterial growth only against B. cereus at 125 µg/mL. 
 




Figure 4: Effect of 6c, 7c, 9 and 10 on viability of human 
neutrophils by MTT assay. Data are presented as mean ± 
SEM of n=6-9 independent experiments. **p <0.01 relative to 
the vehicle group. 
 
When testing an antimicrobial activity, it is important to 
evaluate the lack of toxicity for the host of the synthesized 
compounds. Therefore, since the compounds 6c, 7c, 9 and 10 
exerted the most relevant effects against human pathogens, they 
were primarily tested at 30 and 100 µM for potential cytotoxic 
effects in freshly isolated human neutrophils
10
 by the use of two 
different approaches: the MTT (3[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) colorimetric assay
11
 and by flow 
cytometry analysis
12,13
 of cell apoptosis and survival.
14
 Human 
neutrophils cell types have already been used for assaying the 
cytotoxic effects of different semi-synthetic alkaloids with 
antibacterial activity.
12
 All the compounds displayed significant 
cytotoxicity at 100 µM. However, none of the compounds tested 
exerted any cytotoxicity at 30 µM on neutrophils (Figure 4). In 
fact, this dose was 5 to 11-fold higher than the IC50 required to 
kill S. aureus, E. faecalis, S. typhi and E. coli 405 (IC50 values 
ranged between 2.72 and 6.38 µM, Table 1). 
These results were further confirmed when apoptosis, necrosis 
and survival in this human cell type was determined employing 
the cytofluorimetric assay. In human neutrophils, most of the 
compounds tested barely exerted any significant effect on 
neutrophil apoptosis at the both doses assayed (below the vehicle, 
Figure 5A). When the survival of human cells was determined, 
none of the compounds affected this parameter at 30 µM 
concentration (Figure 5C). In contrast, incubation of the cells 
with 6c and 9 at 100 µM resulted in 98 and 95% of human 
neutrophil necrosis respectively (Figure 5B). Compounds 7c and 
10 caused a 36 and 57% human neutrophil necrosis when they 
were tested at 100 µM. Nevertheless, and as found previously for 
the MTT assay, it is important to note that 30 µM concentration 
is 5-11 fold higher than the IC50 required to kill S. aureus, E. 
faecalis, S. typhi and E. coli 405 (Table 1), the most resistant 
pathogens. 
4. Conclusion 
In summary, a series of 16 tris-aromatic butenolides including 
natural cadiolides A, B, C and analogues has been prepared by 
using a straightforward  one-pot multicomponent synthesis (4 and 
5-10). The antibacterial activity has been evaluated on a panel of 
pathogenic Gram+ and Gram- bacteria, showing MICs as low as 
1.95 µg.mL-1. The SAR studies showed that phenolic hydroxyl 
group is necessary but that the biological activity can be 
dramatically increased by adding bromine atoms on the different 
aromatic rings with optimal number of 3 to 4 bromine atoms (6c, 
7c). We also have shown that a phenolic substituent can be 
advantageously substituted by a furan ring at position 3 of the 
butenolide nucleus (9, 10). In addition, none of the most relevant 
antibacterial compounds showed any cytotoxicity in freshly 
isolated human neutrophils. The straightforward access to the 
cadiolide skeleton will easily allow other structural 












Figure 5: Effect of 6c, 7c, 9 and 10 on neutrophil viability by cytofluorometric analysis. Percentage of apoptotic (A), necrotic 
(B) and survival (C) neutrophils after 24 h incubation with 6c, 7c, 9 and 10. Apoptotic cells were quantified as the percentage of 
total population of annexin V+, PI− cells, late apoptotic, and/or necrotic cells as annexin V+ and PI+, and viable nonapoptotic 
cells as annexin V− and PI−. The columns are the mean ± SEM of n=3 independent experiments. Representative flow cytometry 
panels showing the effects of control, vehicle, 6c, 7c, 9 and 10 on neutrophil apoptosis, necrosis and survival have been included. 
*p <0.05 or **p <0.01 relative to the vehicle group. 
 
5. Materials and Methods 
General: All reactions were carried out under a nitrogen or 
argon atmosphere with dry solvents under anhydrous conditions, 
unless otherwise noted. Dry tetrahydrofuran (THF), methylene 
chloride (CH2Cl2), and toluene were obtained by distillation 
(from CaH2 for CH2Cl2, sodium/benzophenone for THF and from 
sodium for toluene). Methanol (MeOH), N,N'-
dimethylformamide (DMF) and dimethylsulfoxide (DMSO) were 
purchased in anhydrous form and used without further 
purification. Ethyl acetate (EtOAc), diethyl ether (Et2O), 
methylene chloride (CH2Cl2), and cyclohexane were purchased at 
ACS grade quality and used without further purification. 
Reagents were purchased at the highest commercial quality and 
used without further purification. Yields refer to 
chromatographically and spectroscopically (1H NMR and 13C 
NMR) homogeneous materials. Reactions were monitored by 
thin-layer chromatography (TLC) carried out on Merck silica gel 
plates with QF-254 indicator and an ethanolic solution of 
ammonium molybdate or potassium permanganate and heat as 
developing agents. E. Merck silica gel (60, particle size 0.040-
0.063 mm) was used for flash column chromatography. NMR 
spectra were recorded on Bruker Avance DMX-300 instrument 
and calibrated using residual undeuterated solvent as an internal 
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C NMR in 
[D6]Acetone). The following abbreviations were used to describe 
  
the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, 
quint = quintet, m = multiplet, pent = pentet, hex = hextet, br = 
broad. IR spectra were recorded on a Perkin-Elmer Spectrum 
One FTIR spectrometer with diamond ATR accessory.  
UPLC-PDA Analysis. Samples dissolved in MeOH were 
injected onto a Waters Acquity UPLC system (Milford, MA, 
USA) equipped with a binary solvent manager, simple manager, 
column compartment and 2996 PDA detector, connected to 
Waters Masslynx 4.1 software. The separation was carried out 
using a Waters BEH C18 column (2.1 x 100 mm, 1.7 µm) at 37 
ºC. The optimal chromatographic conditions were established: 
solvent system, phase A, 0.1% trifluoroacetic acid in water and 
phase B, 0.1% trifluoroacetic acid in acetonitrile; gradient 
separation system: 80% A at 0 min for 1 min to 100% B at 5 min 
for 2 min, then 80% A at 8 min for 2 min; flow rate 0.4 mL/min 
and injection volume of 2-5 µL. 
UPLC-Q-TOF Analysis: High resolution (HRMS) data were 
recorded on a Waters Xevo quadrupole time-of-flight (Q-TOF) 
spectrometer (Waters Corp., Milford, MA, USA) coupled to an 
Acquity UPLC system (Waters Corp., Milford, MA, USA) via an 
electrospray ionization (ESI) interface. Separation was performed 
on a Waters Acquity BEH C18 column (50 x 2.1 mm i.d., 1.7 
µm). The solvent system consisted of 0.1% formic acid in 
acetonitrile (phase A) and 0.1% formic acid in ultrapure water 
(phase B). Gradient conditions were as follows: 20% B at 0 min 
to 100% A in 3 min, held for 2 min, returned to 20% B in 1 min, 
and equilibrated for 2 min before the next injection; the flow rate 
was 0.2 mL/min; the column and sample temperatures were kept 
at 37ºC and 4ºC, respectively; the sample injection volume was 1 
µL. The ESI source was operated in positive ionization mode 
using leucine-encephaline as reference mass ([M+H]+ ion m/z 
556.2771). The capillary and cone voltages were set at 3.0 kV 
and 45 kV, respectively. The temperature of the source and 
desolvation was set at 120 ºC and 300 ºC, respectively. The cone 
and desolvation gas (nitrogen) flows were 500 L h-1 and 50 L h-
1. The collision energy was set at 5 eV. ESI data acquisition was 
collected in Centroid mode in a full scan range from m/z 50-1500 
at 0.2 s per scan. All data were acquired using MasslynkTM 
NT4.1 software (Waters Corp., Milford, MA, USA).  
Purity for all final compounds was checked by HPLC and  
was determined ≥95%, each showed a parent mass ion consistent 
with the desired structure (HRMS). 
General procedure for the synthesis of Dioxinones 2a-d 
(Procedure A):
5a
 To a stirred solution of acid (1 equiv.) in 
CH2Cl2 (for a solution of 0.1 mol.L
–1
) were added oxalyl chloride 
[(COCl)2; 1.25 equiv.] and DMF (0.004 equiv.) at room 
temperature. After 1.5 h, the solvent and the excess oxalyl 
chloride were removed by evaporation under vacuum. CH2Cl2 
(for a solution of 0.1 mol L
–1
), N,O-dimethylhydroxylamine (1.4 
equiv.), and Et3N (3 equiv.) were then successively added at 
room temperature. After 2 h, the reaction was quenched at room 
temperature with a saturated solution of NaHCO3 and the mixture 
extracted twice with CH2Cl2. The combined organic layers were 
then washed with a saturated solution of NH4Cl and brine. The 
organic layer was then dried with anhydrous MgSO4, filtered, and 
concentrated under vacuum to afford the crude Weinreb amine.  
To a stirred solution of diisopropylamine (DIPA; 3 equiv.) in 
THF (for a solution of 0.1 mol.L
–1
) was added n-Butyl lithium 
(nBuLi, 1.2 M in hexane, 3.1 equiv.) at –78 °C. After 30 min at 0 
°C, the medium was recooled to –78 °C and freshly distilled tBu 
acetate (3 equiv.) was added. After 30 min at –78 °C, crude 
Weinreb amide (1 equiv.) was added at this temperature. After 1 
h, the reaction was quenched at room temperature with a 
saturated solution of NaHCO3 and the mixture extracted twice 
with EtOAc. The combined organic layers were then washed 
with a saturated solution of NH4Cl. The organic layer was then 
dried with anhydrous MgSO4, filtered, and concentrated under 
vacuum to afford the crude tert-butyl ester.  
To a stirred solution of tert-butyl ester (1 equiv.) in acetone 
(10 equiv.) were added acetic anhydride (15 equiv.) and sulfuric 
acid (1 equiv.) at 0 °C. The medium was then warmed slowly to 
room temperature over 10 min. After 45 min, the reaction was 
quenched at room temperature with an aqueous solution 
containing sodium carbonate (30 equiv.) and EtOAc (100 mL) 
was added. The biphasic medium was then stirred for 40 min 
(hydrolysis of the remaining acetic anhydride) and the aqueous 
layer was extracted twice with EtOAc. The combined organic 
layers were then washed with a saturated solution of NH4Cl. The 
organic layer was dried with anhydrous MgSO4, filtered and 
concentrated under vacuum. The crude residue was finally 
purified by flash chromatography silica gel using an appropriate 
gradient of a cyclohexane/EtOAc mixture as eluent to give the 
desired dioxinone. 
6-(4-methoxyphenyl)-2,2-dimethyl-4H-1,3-dioxin-4-one 
(2a) [87769-44-6]: Following procedure A, 4-methoxybenzoic 
acid (3.41 g, 20 mmol) was used to afford 2a as yellow solid with 
77% yield (3.57 g, 15.3 mmol) after purification by flash 
chromatography on silica gel (cyclohexane/EtOAc 80:20). mp: 
68°C; 
1
H NMR (300 MHz, CDCl3): δ 1.77 (s, 6H), 3.84 (s, 3H), 
5.77 (s, 1H), 6.92 (d, J = 9.0 Hz, 2H), 7.71 (d, J = 9.0 Hz, 2H); 
13
C NMR (75 MHz, CDCl3): δ 25.2, 55.7, 89.5, 106.5, 114.4, 
123.5, 128.4, 162.4, 163.0, 165.1; IR (neat): 2999, 2940, 2842, 
1721, 1607, 1513, 1363, 1252, 1179, 1027, 804 cm
-1
; MS (ESI): 
m/z 235 (M + H
+
); HRMS (ESI): calcd for [C13H14O4 + H]
+
 
235.0970; Found 235.0976. 
6-(3-bromo-4-methoxyphenyl)-2,2-dimethyl-4H-1,3-dioxin-
4-one (2b): Following procedure A, 3-bromo-4-methoxybenzoic 
acid (4.44 g, 19.2 mmol) was used to afford 2b as a orange solid 
in 23% yield (1.37 g, 4.42 mmol) after purification by flash 
chromatography on silica gel (cyclohexane/EtOAc, 80:20), m.p. 
120°C. 
1
H NMR (300 MHz, CDCl3): δ = 7.86 (d, J = 2.1 Hz, 
1H), 7.62 (dd, J = 8.7, 2.1 Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 5.78 
(s, 1H), 3.94 (s, 3H), 1.78 (s, 6H) ppm. 
13
C NMR (75 MHz, 
CDCl3): δ = 163.6, 161.8, 158.9, 131.5, 127.2, 124.7, 112.3, 
111.7, 106.8, 90.4, 56.6, 25.1 ppm. IR (neat): 1713, 1597, 1498, 
1357, 1251, 1203, 1037, 1013, 994, 899, 806 cm
-1
. MS (ESI): m/z 




dioxin-4-one (2c): Following procedure A, 3,5-dibromo-4-
methoxybenzoic acid (4.90 g, 15.8 mmol) was used to afford 2c 
as a orange solid in 74% yield (4.57 g, 11.7 mmol) after 
purification by flash chromatography on silica gel 
(cyclohexane/EtOAc, 90:10), m.p. 127°C. 
1
H NMR (300 MHz, 
CDCl3): δ = 7.80 (s, 2H), 5.81 (s, 1H), 3.91 (s, 3H), 1.78 (s, 6H) 
ppm. 
13
C NMR (75 MHz, CDCl3): δ = 161.8, 161.0, 157.2, 130.6, 
129.6, 118.9, 107.2, 92.4, 60.9, 25.1 ppm. IR (neat): 1716, 1616, 
1381, 1340, 1260, 1199, 984, 904, 830, 743 cm
-1
. MS (ESI): m/z 




[1293991-93-1]. Following procedure A, 2-furoic acid  (2.24 g, 
20 mmol) was used to afford 2d as red oil with 57% yield (2.20 
g, 11.3 mmol) after purification by flash chromatography on 
silica gel (cyclohexane/EtOAc 80:20). 1H NMR (300 MHz, 
CDCl3): δ 1.71 (s, 6H), 5.74 (s, 1H), 6.49 (dd, J = 1.7, 3.6 Hz, 
1H), 6.86 (d, J = 3.6 Hz, 1H), 7.53 (brs, 1H); 13C NMR (75 
MHz, CDCl3): δ 25.0, 89.6, 107.0, 112.5, 114.2, 146.2, 146.3, 
  
156.4, 161.6; IR (neat): 3134, 3000, 2945, 1727, 1679, 1641, 




Bromine (0.54 mL, 10.5 mmol) in acetic acid (1.7 mL) was 
added dropwise to a mixture of 4-methoxyacetophenone (758 
mg, 5 mmol) and sodium acetate (1.28 g, 15.5 mmol) in acid 
acetic (10 mL) at room temperature over 10 min. The reaction 
mixture was stirred for 1 h at room temperature. H2O (30 mL) 
was added and the solid was filtered, washed with H2O and dried 
under high vacuum to afford 3-bromo-4-methoxyacetophenone 
11b as a white solid in 88% yield (1.01 g, 4.4 mmol). M.p. 86 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.17 (s, 1H), 7.91 (d, J = 8.7 
Hz, 1H), 6.93 (d, J = 8.7 Hz, 1H), 3.97 (s, 3H), 2.56 (s, 3H) ppm. 
13
C NMR (75 MHz, CDCl3): δ = 195.8, 159.7, 134.0, 131.4, 
129.6, 112.0, 111.2, 56.6, 26.5 ppm. IR (neat): 1670, 1590, 1260, 
1230, 1043, 1012, 817, 590 cm
-1
. MS (APCI): m/z (%) = 228 
(100), 229 (10) [M - H
+
]. 
3,5-dibromo-4-methoxyacetophenone (11c) [79324-79-1]: 
Bromine (1.63 mL, 31.5 mmol) in acetic acid (5 mL) was added 
dropwise to a mixture of 4-hydroxyacetophenone (2.08 g, 15 
mmol) and sodium acetate (3.85 g, 46.5 mmol) in acid acetic (35 
mL) at room temperature over 20 min. The reaction mixture was 
stirred for 1 h at room temperature. H2O (75 mL) was added and 
the solid was filtered, washed with H2O and dried under high 
vacuum to afford 3,5-dibromo-4-hydroxyacetophenone 12 as a 
white solid. To a stirred solution of 12 in DMF (50 mL) was 
added K2CO3 (4.15 g, 30 mmol) in portions, followed by the 
addition of MeI (3.9 mL, 60 mmol), and the mixture was stirred 
at room temperature for 24 h. The reaction mixture was taken in 
EtOAc (100 mL) and washed successively with H2O (50 mL), 1N 
HCl (50 mL), saturated solution of NaHCO3 (50 mL), and brine 
(2 x 50 mL). The organic layer was dried with Na2SO4, filtered 
and concentrated under vacuum to afford 3,5-bromo-4-
methoxyacetophenone 11c as a white solid in 96% yield (4.45 g, 
14.4 mmol). M.p. 83 °C. 
1
H NMR (300 MHz, CDCl3): δ = 8.08 
(s, 2H), 3.93 (s, 3H), 2.56 (s, 3H) ppm. 
13
C NMR (75 MHz, 
CDCl3): δ = 194.7, 158.2, 135.2, 133.0, 118.8, 60.9, 26.6 ppm. IR 
(neat): 1684, 1380, 1349, 1263, 979, 736, 592 cm
-1
. MS (APCI): 
m/z (%) = 308 (55), 228 (100) [M - H
+
]. 
General Procedure for the synthesis of α-bromo-ketones 
13b-c (Procedure B): To a stirred solution of acetophenones 
11b-c (1 equiv.) in THF (30 mL) was added 
trimethylphenylammonium tribromide (1.05 equiv.) at 0 °C. The 
reaction mixture was stirred at room temperature for 12 h. The 
solid was filtered, and to the filtrate was added EtOAc (20 mL). 
The organic layer was washed successively with H2O (20 mL) 
and brine (20 mL). The organic layer was then dried over 
Na2SO4, filtered and concentrated under vacuum. The crude 
residue was then purified by flash chromatography on silica gel 
using an appropriate gradient of cyclohexane/EtOAc as eluent to 
give the desired α-bromo-ketone 13b-c. 
2-bromo-1-(3-bromo-4-methoxyphenyl)ethanone (13b) 
[6096-83-9]: Following procedure B, 3-bromo-4-
methoxyacetophenone 11b (1.01 g, 4.4 mmol) was used to afford 
13b as a white solid in 89% yield (1.20 g, 3.9 mmol) after 
purification by flash chromatography on silica gel 
(cyclohexane/EtOAc, 90:10), m.p. 113 °C. 
1
H NMR (300 MHz, 
CDCl3): δ = 8.19 (d, J = 2.1 Hz, 1H), 7.94 (dd, J = 8.7, 2.1 Hz, 
1H), 6.95 (d, J = 8.7 Hz, 1H), 4.37 (s, 2H), 3.98 (s, 3H) ppm. 
13
C 
NMR (75 MHz, CDCl3): δ = 189.1, 160.4, 134.5, 130.5, 128.0, 
112.4, 111.4, 56.7, 30.4 ppm. IR (neat): 1688, 1586, 1493, 1272, 
1247, 1180, 1045, 1002, 813, 660, 606, 586 cm
-1
. MS (APCI): 




[1563037-34-2] (13c): Following procedure B, 3,5-dibromo-4-
methoxyacetophenone 11c (4.36 g, 14.2 mmol) was used to 
afford 13c as a white solid in 99% yield (5.42 g, 14.0 mmol) after 
purification by flash chromatography on silica gel 
(cyclohexane/EtOAc, 90:10), m.p. 101 °C. 
1
H NMR (300 MHz, 
CDCl3): δ = 8.12 (s, 2H), 4.36 (s, 2H), 3.96 (s, 3H) ppm. 
13
C 
NMR (75 MHz, CDCl3): δ = 188.3, 158.9, 133.6, 132.0, 119.0, 
61.0, 30.0 ppm. IR (neat): 1698, 1469, 1377, 1273, 1178, 985, 
851, 735, 608 cm
-1
.  
General Procedure for the Synthesis of α-hydroxy-ketones 
1a-c (Procedure C): Sodium formate (3 equiv.) was stirred in 
ethanol (0.1 mol.L
–1
) for 15 min and α-bromo ketone 13 (1 
equiv.) was then added. The mixture was stirred at 70 °C 
overnight. The solution was filtered hot and concentrated under 
vacuum. The crude residue was then purified by flash 
chromatography on silica gel using an appropriate gradient of 
cyclohexane/EtOAc as eluent to give the desired α-hydroxy-
ketone 1a-c. 
2-hydroxy-1-(3-bromo-4-methoxyphenyl)--ethanone (1b) 
[927802-90-2]: Following procedure C, 2-bromo-1-(3-bromo-4-
methoxyphenyl)ethanone 13b (1.16 g, 3.8 mmol) was used to 
afford 1b as a white solid in 58% yield (533 mg, 2.2 mmol) after 
purification by flash chromatography on silica gel 
(cyclohexane/EtOAc, 80:20), m.p. 115 °C. 
1
H NMR (300 MHz, 
CDCl3): δ = 8.12 (d, J = 2.1 Hz, 1H), 7.87 (dd, J = 8.7, 2.1 Hz, 
1H), 6.96 (d, J = 8.7 Hz, 1H), 4.80 (d, J = 3.6 Hz, 2H), 3.98 (s, 
3H), 3.47 (t, J = 3.6 Hz, 1H) ppm. 
13
C NMR (75 MHz, CDCl3): δ 
= 196.1, 160.6, 133.3, 129.0, 127.5, 112.5, 111.5, 65.2, 56.7 ppm. 
IR (neat): 3389, 1671, 1590, 1414, 1256, 1209, 1108, 1049, 




(1c): Following procedure C, 2-bromo-1-(3,5-di bromo-4-
methoxyphenyl)ethanone 13c (5.41 g, 14 mmol) was used to 
afford 1c as a white solid in 60% yield (2.71 g, 8.4 mmol) after 
purification by flash chromatography on silica gel 
(cyclohexane/EtOAc, 80:20), m.p. 124 °C. 
1
H NMR (300 MHz, 
CDCl3): δ = 8.06 (s, 2H), 4.81 (s, 2H), 3.96 (s, 3H), 3.34 (brs, 
1H) ppm. 
13
C NMR (75 MHz, CDCl3): δ = 195.6, 159.2, 132.4, 




3,5-dibromo-4-methoxybenzaldehyde (3c) [108940-96-1]: 
Bromine (1.63 mL, 31.5 mmol) in acetic acid (5 mL) was added 
dropwise to a mixture of 4-hydroxybenzaldehyde (1.85 g, 15 
mmol) and sodium acetate (3.85 g, 46.5 mmol) in acid acetic (35 
mL) at room temperature over 20 min. The reaction mixture was 
stirred for 1 h at room temperature. H2O (75 mL) was added and 
the solid was filtered, washed with H2O and dried under high 
vacuum to afford 3,5-dibromo-4-hydroxybenzaldehyde 14 as a 
white solid. 
To a stirred solution of 14 in DMF (50 mL) was added K2CO3 
(4.15 g, 30 mmol) in portions, followed by the addition of MeI 
(3.9 mL, 60 mmol), and the mixture was stirred at room 
temperature for 24 h. The reaction mixture was taken in EtOAc 
(100 mL) and washed successively with H2O (50 mL), 1M HCl 
(50 mL), saturated solution of NaHCO3 (50 mL), and brine (2 x 
50 mL). The organic layer was dried with Na2SO4, filtered and 
concentrated under vacuum. The crude product was purified by 
chromatography on silica gel by using cyclohexane/EtOAc 
(90:10) as eluent to give 3,5-dibromo-4-methoxybenzaldehyde 3c 
as a white solid in 82% yield (3.62 g, 12.3 mmol). M.p. 97 °C. 
1
H 
NMR (300 MHz, CDCl3): δ = 9.86 (s, 1H), 8.02 (s, 2H), 3.96 (s, 
3H) ppm. 
13
C NMR (75 MHz, CDCl3): δ = 188.6, 159.3, 134.4, 
  
134.1, 119.5, 61.0 ppm. IR (neat): 1685, 1545, 1468, 1365, 1258, 
1186, 979, 877, 730, 653, 531 cm
-1
.  
General Procedure for the Synthesis of Cadiolide 
analogues 5-10: Toluene (for a solution of 1.0 mol.L
–1
), Et3N 
(2.0 equiv.) and the appropriate α-hydroxy-ketone 1a-c (1 
equiv.), dioxinone 2a-d (2 equiv.) and aldehyde 3a-c (1 equiv.) 
were added to a 15 mL tube flushed with argon. The tube was 
sealed and then heated in a microwave reactor. Over 1.5 min, the 
temperature was raised to 150 °C, held for 5 min, and then cooled 
for 10 min. The reaction was quenched at room temperature with 
1M HCl and the mixture extracted with EtOAc. The combined 
organic layers were then dried with Na2SO4, filtered and 
concentrated under vacuum. Filtration through a plug of silica 
and elution with (cyclohexane/EtOAc, 80:20) afforded a mixture 
of bis-methoxylated and mono-methoxylated acylfuranones 4, 
which was used directly without further purification (partial de-
methoxylation resulted during the microwave-assisted multi-
component recation).  
To a stirred solution of bis-methoxylated and mono-
methoxylated acylfuranones 4 (obtained above) in CH2Cl2 (5 mL) 
was added BBr3 (10 equiv.) at -78 °C. The mixture was then 
slowly warmed to room temperature over 20 h. The reaction was 
quenched at –78 °C with MeOH then at room temperature with 
H2O and the mixture extracted twice with EtOAc. The combined 
organic layers were then dried with Na2SO4, filtered and 
concentrated under vacuum. The crude product was purified by 
flash chromatography on silica gel using a gradient of 
EtOAc/MeOH (100:0 to 95:5) to give cadiolide analogues 5-10. 
(Z)-3-(4-hydroxybenzoyl)-5-(4-hydroxybenzylidene)-4-(4-
hydroxyphenyl)furan-2(5H)-one (5a): Following procedure D, 
α-hydroxy-ketone 1a (83 mg, 0.5 mmol), dioxinone 2a (234 mg, 
1.0 mmol) and 4-methoxybenzaldehyde 3a (0.06 mL, 0.5 mmol) 
were used to afford 5a as yellow solid in 72% yield (142 mg, 
0.36 mmol). Analyses are similar to those described in the 
literature.
5d
 M.p. 262 °C. 
1
H NMR (300 MHz, [D6]DMSO): δ = 
10.69 (brs, 1H), 10.28 (brs, 1H), 10.15 (brs, 1H), 7.74 (d, J = 8.7 
Hz, 2H), 7.68 (d, J = 8.7 Hz, 2H), 7.22 (d, J = 8.7 Hz, 2H), 6.89 
(d, J = 8.7 Hz, 2H), 6.82 (d, J = 8.7 Hz, 2H), 6.78 (d, J = 8.7 Hz, 
2H), 6.33 (s, 1H) ppm. 
13
C NMR (75 MHz, [D6]DMSO): δ = 
188.0, 166.1, 163.2, 159.6, 159.5, 155.9, 144.6, 133.0, 132.1, 
130.8, 127.4, 124.0, 121.4, 119.3, 116.4, 116.1, 115.8, 115.5 




Following procedure D, α-hydroxy-ketone 1a (41 mg, 0.25 
mmol), dioxinone 2a (117 mg, 0.5 mmol) and 3-bromo-4-
methoxybenzaldehyde 3b (54 mg, 0.25 mmol) were used to 
afford 5b as yellow solid in 39% yield (43 mg, 0.09 mmol). M.p. 
159 ºC. 
1
H NMR (300 MHz, [D6]DMSO): δ = 11.03 (brs, 1H), 
10.61 (brs, 1H), 10.09 (brs, 1H), 8.08 (d, J = 2.1 Hz, 1H), 7.76 
(dd, J = 8.7, 2.1 Hz, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.23 (d, J = 
8.6 Hz, 2H), 7.05 (d, J = 8.7 Hz, 1H), 6.81 (d, J = 8.8 Hz, 2H), 
6.77 (d, J = 8.6 Hz, 2H), 6.36 (s, 1H) ppm. 
13
C NMR (75 MHz, 
[D6]DMSO): δ = 188.3, 166.3, 163.5, 160.0, 155.9, 145.7, 135.1, 
132.6, 132.2, 131.2, 127.7, 126.1, 122.4, 119.6, 117.1, 116.1, 
115.8, 114.9, 110.3 ppm. IR (neat): υ = 3233, 1729, 1576, 1557, 
1501, 1440, 1410, 1371, 1274, 1221, 1152, 1041, 863, 841 cm
–1
. 




(5c): Following procedure D, α-hydroxy-ketone 1a (41 mg, 0.25 
mmol), dioxinone 2b (156 mg, 0.5 mmol) and 3-bromo-4-
methoxybenzaldehyde 3b (54 mg, 0.25 mmol) were used to 
afford 5c as yellow solid in 38% yield (52 mg, 0.09 mmol). M.p. 
219 ºC. 
1
H NMR (300 MHz, [D6]DMSO): δ = 11.10 (brs, 1H), 
10.62 (brs, 1H), 10.11 (brs, 1H), 8.09 (d, J = 2.1 Hz, 1H), 7.95 
(d, J = 2.2 Hz, 1H), 7.76 (dd, J = 8.7, 2.1 Hz, 1H), 7.69 (dd, J = 
8.5, 2.2 Hz, 1H), 7.25 (d, J = 8.8 Hz, 2H), 7.05 (d, J = 8.5 Hz, 
1H), 6.93 (d, J = 8.7 Hz, 1H), 6.79 (d, J = 8.8 Hz, 2H), 6.37 (s, 
1H) ppm. 
13
C NMR (75 MHz, [D6]DMSO): 187.4, 166.2, 160.1, 
159.8, 157.1, 156.1, 145.8, 135.8, 133.4, 132.5, 132.3, 131.4, 
129.0, 126.1, 121.5, 119.5, 117.1, 116.1, 115.5, 110.3, 110.0 
ppm. IR (neat): υ = 3336, 1747, 1714, 1584, 1556, 1504, 1409, 
1383, 1303, 1218, 1179, 1150, 1081, 848, 825 cm
–1
. HRMS 
(ESI): calculated for C24H15Br2O6 558.9217 found 558.9201. 
(Z)-3-(3,5-dibromo-4-hydroxybenzoyl)-5-(3,5-dibromo-4-
hydroxybenzylidene)-4-(4-hydroxyphenyl)furan-2(5H)-one 
(5d): Following procedure D, α-hydroxy-ketone 1a (44 mg, 0.26 
mmol), dioxinone 2c (204 mg, 0.52 mmol) and 3,5-dibromo-4-
methoxybenzaldehyde 3c (76 mg, 0.26 mmol) were used to 
afford 5d as a yellow solid in 38% yield (70 mg, 0.01 mmol). 
Decomp. 150 °C. 
1
H NMR (300 MHz, [D6]DMSO): δ = 10.15 
(brs, 1H), 8.12 (s, 2H), 7.97 (s, 2H), 7.21 (d, J = 8.7 Hz, 2H), 
6.79 (d, J = 8.7 Hz, 2H), 6.42 (s, 1H) ppm. 
13
C NMR (75 MHz, 
[D6]DMSO): δ = 186.0, 165.6, 159.9, 157.7, 156.0, 152.1, 146.6, 
134.7, 133.9, 131.3, 129.5, 127.6, 121.0, 119.0, 115.9, 113.7, 
112.1, 111.5 ppm. IR (neat): 3208, 1748, 1578, 1476, 1376, 
1297, 1152, 981, 679 cm
-1
; MS (ESI): m/z (%) = 719 (15), 718 
(19), 717 (70), 716 (30), 715 (100), 714 (22), 713 (60), 711 (15). 




Following procedure D, α-hydroxy-ketone 1b (61 mg, 0.25 
mmol), dioxinone 2a (117 mg, 0.5 mmol) and 3-bromo-4-
methoxybenzaldehyde 3b (54 mg, 0.25 mmol) were used to 
afford 6b as yellow solid in 37% yield (51 mg, 0.09 mmol). M.p. 
148 ºC. 
1
H NMR (300 MHz, [D6]DMSO): δ = 10.92 (brs, 1H), 
10.71 (brs, 1H), 8.30 (brs, 1H), 8.09 (d, J = 1.9 Hz, 1H), 7.76 
(dd, J = 8.6, 1.9 Hz, 1H), 7.72 (d, J = 8.8 Hz, 2H), 7.49 (d, J = 
2.1 Hz, 1H), 7.25 (dd, J = 8.4, 2.1 Hz, 1H), 7.03 (d, J = 8.6 Hz, 
1H), 6.99 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 8.8 Hz, 2H), 6.35 (s, 
1H) ppm. 
13
C NMR (75 MHz, [D6]DMSO): 187.9, 166.1, 163.6, 
156.5, 156.1, 154.9, 145.8, 135.9, 133.8, 132.6, 132.3, 130.3, 
127.7, 126.0, 121.0, 117.1, 116.8, 115.9, 115.2, 110.3, 109.9 
ppm. IR (neat): υ = 3160, 1732, 1561, 1548, 1504, 1406, 1370, 
1287, 1225, 1161, 1042, 866, 848 cm
–1
. HRMS (ESI): calculated 
for C24H15Br2O6 558.9217 found 558.9219. 
(Z)-3-(3-bromo-4-hydroxybenzoyl)-5-(3-bromo-4-
hydroxybenzylidene)-4-(3-bromo-4-hydroxyphenyl)furan-
2(5H)-one (6c): Following procedure D, α-hydroxy-ketone 1b 
(123 mg, 0.5 mmol), dioxinone 2b (313 mg, 1.0 mmol) and 
aldehyde 3b (110 mg, 0.5 mmol) were used to afford 6c as an 
orange solid in 44% yield (158 mg, 0.22 mmol). Decomp. 98 °C. 
1
H NMR (300 MHz, [D6]DMSO): δ = 11.47 (brs, 1H), 11.06 
(brs, 1H), 10.93 (brs, 1H), 8.08 (d, J = 2.1 Hz, 1H), 7.97 (d, J = 
2.1 Hz, 1H), 7.75 (dd, J = 8.7, 2.1 Hz, 1H), 7.70 (dd, J = 8.7, 2.1 
Hz, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.23 (dd, J = 8.7, 2.1 Hz, 1H), 
7.05 (d, J = 8.7 Hz, 1H), 6.98 (d, J = 8.7 Hz, 1H), 6.95 (d, J = 8.7 
Hz, 1H), 6.36 (s, 1H) ppm. 
13
C NMR (75 MHz, [D6]DMSO): δ = 
186.7, 165.7, 159.5, 156.2, 155.9, 155.7, 145.4, 135.7, 135.0, 
133.7, 132.1, 131.0, 130.2, 128.7, 125.8, 122.0, 120.7, 116.8, 
116.5, 116.0, 115.5, 110.0, 109.7 (2C) ppm. IR (neat): 2925, 
1745, 1555, 1495, 1367, 1291, 974, 820 cm
-1
; MS (ESI): m/z (%) 
= 641 (39), 640 (22), 639 (100), 638 (32), 637 (58), 636 (30). 
  




hydroxybenzylidene)furan-2(5H)-one (6e): Following 
procedure D, α-hydroxy-ketone 1b (123 mg, 0.5 mmol), 
dioxinone 2b (313 mg, 1.0 mmol) and 3,5-dibromo-4-
methoxybenzaldehyde 3c (147 mg, 0.5 mmol) were used to 
afford 6e as a brown solid in 61% yield (220 mg, 0.31 mmol). 
Decomp. 182 °C. 
1
H NMR (300 MHz, [D6]DMSO): δ = 11.48 
(brs, 1H), 10.94 (brs, 1H), 10.65 (brs, 1H), 8.10 (s, 2H), 7.97 (d, 
J = 2.0 Hz, 1H), 7.70 (dd, J = 8.5, 2.0 Hz, 1H), 7.49 (d, J = 2.0 
Hz, 1H), 7.22 (dd, J = 8.4, 2.0 Hz, 1H), 6.97 (d, J = 8.5 Hz, 1H), 
6.95 (d, J = 8.5 Hz, 1H), 6.39 (s, 1H) ppm. 
13
C NMR (75 MHz, 
[D6]DMSO): δ = 186.6, 165.6, 159.7, 156.4, 155.6, 152.1, 146.5, 
135.2, 134.8, 133.8, 131.1, 130.3, 128.6, 127.6, 122.8, 120.6, 
116.6, 116.2, 113.6, 112.1 (2C), 109.8 ppm. IR (neat): 3188, 
1737, 1476, 1403, 1367, 1296, 1191, 978, 708, 635, 545 cm
-1
. 
MS (ESI): m/z (%) = 719 (26), 718 (21), 717 (100), 716 (55), 715 
(96), 714 (30), 713 (80), 711 (27). HRMS (ESI): calculated for 
C24H13Br4O6 716.7407 found 716.7411. 
Cadiolide C: (Z)-5-(3-bromo-4-hydroxybenzylidene)-4-(3-
bromo-4-hydroxyphenyl)-3-(3,5-dibromo-4-
hydroxybenzoyl)furan-2(5H)-one [1414518-14-1] (6f): 
Following procedure D, α-hydroxy-ketone 1b (123 mg, 0.5 
mmol), dioxinone 2c (392 mg, 1.0 mmol) and 3-bromo-4-
methoxybenzaldehyde 3b (110 mg, 0.5 mmol) were used to 
afford 6f as an orange solid in 47% yield (168 mg, 0.24 mmol). 
Decomp. 116 °C. 
1
H NMR (300 MHz, [D6]DMSO): δ = 11.11 
(brs, 1H), 10.95 (brs, 1H), 8.09 (s, 1H), 7.96 (s, 2H), 7.77 (d, J = 
8.4 Hz, 1H), 7.50 (s, 1H), 7.21 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 
8.4 Hz, 1H), 6.97 (d, J = 8.4 Hz, 1H), 6.38 (s, 1H) ppm. 
13
C 
NMR (75 MHz, [D6]DMSO): δ = 185.7, 165.6, 156.9, 156.2, 
156.0, 155.7, 145.5, 135.8, 133.8, 132.2, 130.3, 129.8, 125.8, 
121.0, 120.7, 116.8, 116.4, 116.0, 111.4 (2C), 110.0, 109.7 ppm. 
IR (neat): 3073, 1739, 1547, 1400, 1295, 979, 685 cm
-1
; MS 
(ESI): m/z (%) = 719 (25), 718 (24), 717 (70), 716 (30), 715 
(100), 714 (22), 713 (72), 711 (17). HRMS (ESI): calculated for 
C24H13Br4O6 716.7407 found 716.7406. 
(Z)-3-(3-bromo-4-hydroxybenzoyl)-5-(3-bromo-4-
hydroxybenzylidene)-4-(3,5-dibromo-4-
hydroxyphenyl)furan-2(5H)-one (7c): Following procedure D, 
α-hydroxy-ketone 1c (162 mg, 0.5 mmol), dioxinone 2b (313 mg, 
1.0 mmol) and 3-bromo-4-methoxybenzaldehyde 3b (110 mg, 
0.5 mmol) were used to afford 7c as an orange solid in 39% yield 
(140 mg, 0.2 mmol). Decomp. 110 °C. 
1
H NMR (300 MHz, 
[D6]DMSO): δ = 11.48 (brs, 1H), 11.11 (brs, 1H), 8.09 (d, J = 2.1 
Hz, 1H), 7.97 (d, J = 2.1 Hz, 1H), 7.78 (dd, J = 2.1, 8.7 Hz, 1H), 
7.70 (dd, J = 2.1, 8.7 Hz, 1H), 7.55 (s, 2H), 7.06 (d, J = 8.7 Hz, 
1H), 6.96 (d, J = 8.7 Hz, 1H), 6.38 (s, 1H) ppm. 
13
C NMR (75 
MHz, [D6]DMSO): δ = 186.2, 165.6, 159.5, 156.0, 154.8, 152.8, 
145.4, 135.9, 135.2, 132.9, 132.2, 130.8, 128.6, 125.7, 122.8, 
122.5, 116.8, 116.0, 115.8, 111.8, 110.0, 109.6 ppm. IR (neat): 
2919, 1746, 1592, 1296, 1164, 1022, 978, 824, 744, 634 cm
-1
. 
MS (ESI): m/z (%) = 719 (20), 718 (18), 717 (65), 716 (27), 715 
(100), 714 (16), 713 (61), 711 (16). HRMS (ESI): calculated for 
C24H13Br4O6 716.7407 found 716.7400. 
(Z)-3-(3-bromo-4-hydroxybenzoyl)-5-(3,5-dibromo-4-
hydroxybenzylidene)-4-(3,5-dibromo-4-
hydroxyphenyl)furan-2(5H)-one (7e): Following procedure D, 
α-hydroxy-ketone 1c (162 mg, 0.5 mmol), dioxinone 2b (313 mg, 
1.0 mmol) and 3,5-dibromo-4-methoxybenzaldehyde 3c (147 mg, 
0.5 mmol) were used to afford 7e as a brown solid in 21% yield 
(85 mg, 0.11 mmol). Decomp. 110 °C. 
1
H NMR (300 MHz, 
[D6]DMSO): δ = 11.51 (brs, 1H), 10.61 (brs, 1H), 8.13 (s, 2H), 
8.0 (s, 1H), 7.71 (d, J = 8.6 Hz, 1H), 7.55 (s, 2H), 6.96 (d, J = 8.6 
Hz, 1H), 6.42 (s, 1H) ppm. 
13
C NMR (75 MHz, [D6]DMSO): δ = 
186.1, 165.3, 159.7, 154.6, 152.6, 152.2, 146.4, 135.3, 134.7, 
133.4, 133.0, 130.8, 128.5, 127.5, 123.6, 122.3, 116.1, 113.7, 
112.1, 111.9, 111.4, 109.6 ppm. IR (neat): 3201, 1754, 1589, 
1476, 1406, 1296, 1194, 1152, 1021, 977, 816, 740, 634 cm
-1
. 
MS (ESI): m/z (%) = 799 (15), 798 (20), 797 (53), 796 (26), 795 
(96), 794 (32), 793 (100), 791 (51), 789 (12). HRMS (ESI): 
calculated for C24H12Br5O6 794.6512 found 794.6512. 
Cadiolide B: (Z)-3-(3,5-dibromo-4-hydroxybenzoyl)-5-(3,5-
dibromo-4-hydroxybenzylidene)-4-(3,5-dibromo-4-
hydroxyphenyl)furan-2(5H)-one [206763-42-0]: (7g) To a 
solution of acylfuranone 5a (26 mg, 0.065 mmol) in dioxane-H2O 
(2 mL, 1:1) was added dropwise a brominating agent (0.69 mL) 
prepared from Br2 (0.03 mL) and KBr (150 mg) in H2O (1 mL). 
The mixture was stirred for 24h, treated with brine, and extracted 
with Et2O. The organic layer was washed with brine then with 
Na2S2O3. The combined organic layer was then dried over 
Na2SO4, filtered and concentrated under vacuum. The crude 
product was chromatographied on silica gel using a gradient of 
EtOAc/MeOH mixture (100:0 to 90:10) to give Cadiolide B as a 
black solid with 67% yield (38 mg, 0.044 mmol). Analyses are 




H NMR (300 
MHz, [D6]DMSO): 8.12 (s, 2H), 7.91 (s, 2H), 7.55 (s, 2H), 6.40 
(s, 1H) ppm
13
C NMR (75 MHz, [D6]DMSO): δ = 184.3, 165.3, 
156.2, 154.8, 152.6, 146.2, 134.8, 133.7, 133.0, 130.2, 127.1, 
122.8, 122.3, 114.0, 112.2, 112.0, 111.8, 109.7 ppm. MS (ESI): 
m/z 879 (8), 878 (14), 877 (30), 874 (78), 873 (100), 871 (84), 
868 (30), 867 (6). HRMS (ESI): calculated for 
C24H11Br6O6 874.5590 found 874.5598. 
(Z)-5-(3,5-dibromo-4-hydroxybenzylidene)-4-(3,5-
dibromo-4-hydroxyphenyl)-3-(4-hydroxybenzoyl)furan-
2(5H)-one (7h): Following procedure D, α-hydroxy-ketone 1c 
(162 mg, 0.5 mmol), dioxinone 2a (234 mg, 1.0 mmol) and 3,5-
dibromo-4-methoxybenzaldehyde 3c (147 mg, 0.5 mmol) were 
used to afford 7h as a brown solid in 19% yield (69 mg, 0.96 
mmol). Decomp. 128 °C. 
1
H NMR (300 MHz, [D6]DMSO): δ = 
10.67 (brs, 1H), 8.13 (s, 1H), 7.75 (d, J = 8.7 Hz, 2H), 7.55 (s, 
2H), 6.79 (d, J = 8.7 Hz, 2H), 6.41 (s, 1H) ppm. 
13
C NMR (75 
MHz, [D6]DMSO): δ = 187.0, 165.4, 163.4, 153.4, 152.6, 152.2, 
146.2, 134.6, 132.8, 132.4, 127.3 (2C), 124.4, 122.3, 115.5, 
113.2, 112.1, 111.8 ppm. IR (neat): 3073, 1753, 1575, 1476, 
1291, 1246, 1161, 974, 874, 741, 620 cm
-1
. MS (ESI): m/z (%) = 
719 (20), 718 (23), 717 (85), 716 (28), 715 (100), 714 (24), 713 
(74), 711 (30). HRMS (ESI): calculated for C24H13Br4O6 
716.7407 found 716.7394. 
Cadiolide A: (Z)-3-(3,5-dibromo-4-hydroxybenzoyl)-4-(3,5-
dibromo-4-hydroxyphenyl)-5-(4-hydroxybenzylidene)furan-
2(5H)-one [206763-40-8]: (7i) Following procedure D, α-
hydroxy-ketone 1c (162 mg, 0.5 mmol), dioxinone 2c (392 mg, 
1.0 mmol) and p-methoxybenzaldehyde 3a (0.06 mL, 0.5 mmol) 
were used to afford 7i as an orange solid in 18% yield (64 mg, 
0.09 mmol). Decomp. 168 °C. 
1
H NMR (300 MHz, [D6]DMSO): 
δ = 10.56 (brs, 1H), 10.37 (brs, 1H), 7.93 (s, 2H), 7.79 (d, J = 8.7 
Hz, 2H), 7.56 (s, 2H), 6.88 (d, J = 8.7 Hz, 2H), 6.37 (s, 1H) ppm. 
13
C NMR (75 MHz, [D6]DMSO): δ = 185.3, 165.5, 159.9, 156.0, 
155.6, 152.4, 144.6, 133.7, 133.6, 133.0, 129.8, 124.1, 122.7, 
121.1, 118.3, 116.2, 111.7, 111.3 ppm. IR (neat): 3073, 1749, 
1597, 1538, 1293, 1170, 987, 740 cm
-1
. MS (ESI): m/z (%) = 719 
(20), 718 (20), 717 (62), 716 (26), 715 (100), 714 (22), 713 (60), 




hydroxyphenyl)furan-2(5H)-one (8): Following procedure D, 
α-hydroxy-ketone 1a (166 mg, 1.0 mmol), dioxinone 2d (388 
mg, 2.0 mmol) and 4-methoxybenzaldehyde 3a (0.11 mL, 1.0 
mmol) were used to afford 8 as a yellow solid in 37% yield (143 
mg, 0.37 mmol). 
1
H NMR (300 MHz, [D6]DMSO): δ = 10.24 
(brs, 1H), 10.11 (brs, 1H), 7.97 (d, J = 1.8 Hz, 1H), 7.75 (d, J = 
9.0 Hz, 2H), 7.35 (d, J = 3.6 Hz, 1H), 7.28 (dd, J = 6.9, 1.8Hz, 
2H), 6.88 (d, J = 9.0 Hz, 2H), 6.85 (d, J = 6.9, 9.0 Hz, 2H), 6.64 
(dd, J = 3.6, 1.8 Hz, 1H), 6.37 (s, 1H) ppm. 
13
C NMR (75 MHz, 
[D6]DMSO): δ = 176.0, 165.8, 159.8, 159.6, 157.5, 151.3, 149.3, 
144.5, 133.3, 131.0, 124.1, 122.6, 119.9, 119.3, 117.6, 116.2, 
115.9, 113.0 ppm. MS (ESI): m/z = 373 [M – H]
+
. HRMS (ESI): 
calculated for C22H15O6 375.0869 found 375.0857. 
(Z)-5-(3-bromo-4-hydroxybenzylidene)-4-(3-bromo-4-
hydroxyphenyl)-3-(furan-2-carbonyl)furan-2(5H)-one (9): 
Following procedure D, α-hydroxy-ketone 1b (61 mg, 0.25 
mmol), dioxinone 2d (97 mg, 0.5 mmol) and 3-bromo-4-
methoxybenzaldehyde 3b (54 mg, 0.25 mmol) were used to 
afford 9 as a brown solid in 30% yield (40 mg, 0.075 mmol). 
M.p. = 246 °C. 
1
H NMR (300 MHz, [D6]DMSO): δ = 11.05 (brs, 
1H), 10.98 (brs, 1H), 8.10 (d, J = 2.1 Hz, 1H), 8.02 (d, J = 0.6 
Hz, 1H), 7.78 (dd, J = 8.7, 2.1 Hz, 1H), 7.55 (d, J = 2.1 Hz, 1H), 
7.46 (dd, J = 3.9, 0.9 Hz, 1H), 7.29 (dd, J = 8.4, 2.1 Hz, 1H), 
7.04 (t, J = 7.8 Hz, 2H), 6.69 (dd, J = 3.9, 1.8 Hz, 1H), 6.39 (s, 
1H) ppm. 
13
C NMR (75 MHz, [D6]Acetone): δ = 176.3, 166.1, 
156.84, 156.81, 152.8, 149.5, 147.0, 136.8, 134.8, 132.9, 131.1, 
127.6, 123.5, 122.6, 117.6, 117.3, 116.2, 113.6, 110.8, 110.6 
ppm. IR (neat): 2289, 1743, 1600, 1543, 1496, 1453, 1398, 1299, 
1182, 986, 822, 772, 671, 587, 529 cm
-1
. MS (ESI): m/z = 531 [M 
– H]
+




Following procedure D, α-hydroxy-ketone 1c (81 mg, 0.25 
mmol), dioxinone 2d (97 mg, 0.5 mmol) and 3-bromo-4-
methoxybenzaldehyde 3b (54 mg, 0.25 mmol) were used to 
afford 10 as a brown solid in 13% yield (20 mg, 0.03 mmol). 
M.p. > 266 °C. 
1
H NMR (300 MHz, [D6]Acetone): δ = 8.13 (d, 
J=0.7 Hz, 1H), 7.86 (d, J=0.7 Hz, 1H), 7.82 (dd, J = 8.7, 2.1 Hz, 
1H), 7.73 (s, 2H), 7.46 (dd, J = 3.7, 0.7 Hz, 1H), 7.14 (d, J = 8.5 
Hz, 1H), 6.67 (dd, J = 3.7, 1.7 Hz, 1H), 6.47 (s, 1H), 5.63 (s, 
residual CH2Cl2) ppm. 
13
C NMR (75 MHz, [D6]Acetone): δ = 
175.9, 166.0, 156.7, 155.8, 153.6, 152.8, 149.7, 146.9, 136.9, 
134.0, 133.0, 127.5, 124.1, 123.8, 122.8, 117.7, 116.6, 113.7, 
111.7, 111.0 ppm. IR (neat): 3077, 1736, 1643, 1591, 1561, 
1461, 1416, 1331, 1277, 1166, 830, 807, 755, 655, 561 cm
-1
. MS 
(ESI): m/z = 610 [M – H]
+
. HRMS (ESI): calculated for 
C22H12Br3O6 608.8184 found 608.8180. 
Antibacterial activity. The following eight bacteria were 
provided by the Spanish Type Culture Collection (CECT): 
Bacillus cereus (CECT 148), Staphylococcus aureus (CECT 86), 
Enterococcus faecalis (CECT 481), Bacillus subtilis (CECT 35), 
Salmonella typhi (CECT 409), Escherichia coli 405 (CECT 405), 
Escherichia coli 100 (CECT 100) and Erwinia carotovora 
(CECT 225). The minimum inhibitory concentration (MIC) was 
determined as the lowest compound concentration required to 
completely inhibit growth of bacteria, by the 2-fold microtiter 
broth dilution method and according to CLSI guidelines.
7
Each 
compound was dissolved in dimethyl sulfoxide (DMSO), and ten 
2-fold serial dilutions of the stock were prepared. Stock 
suspensions of bacteria were prepared to OD620= 0.001 in 
Nutrient Broth (Difco). Then, this suspension of bacteria (100 
µL) was mixed with serial dilutions of each compound (100 µL) 
in each well of a 96-well of polypropylene microplates and 
incubated at 28ºC or 37ºC, depending on each strain growth 
conditions overnight (18 h). After, bacteria growth was 
determined turbidimetrically at OD620 in each well using a 
microplate reader (Thermo Scientific Multiskan FC multimode). 
Each experiment was performed by triplicate. The antibacterial 
activity was expressed as the MIC range and defined as the 
lowest concentration of test compounds that inhibited bacterial 
growth. Tetracycline hydrochloride was used as a reference 
compound. 
Cytotoxicity studies. The cytotoxicity of the most active 
compounds, 6c, 7c, 9 and 10 was determined at 30 and 100 µM 
on freshly isolated human neutrophils by the use of two different 
approaches: the MTT colorimetric assay and by flow cytometry 
analysis of cell apoptosis and survival.
14 
Human neutrophils were 
obtained from buffy coats of healthy donors by Ficoll-Hypaque 
density gradient centrifugation as described.
10  
MTT assay: The viability of neutrophils was determined 
using the previously described MTT (3[4,5-dimethylthiazol-2-
yl]-2,5-diphenyltetrazolium bromide) colorimetric assay.
11 
100 
µL of neutrophils suspension in supplemented RPMI medium (2 
x 10
5
 cells/mL) was added to each well of a 96-well microtiter 
plate. Cells were incubated in the absence or presence of 
compounds at 37 ºC for 24 h. MTT was freshly prepared at 2 
mg/mL in PBS. 100 µL of MTT solution was added to each well 
and incubated at 37°C for another 3 h. The supernatants were 
discarded and 200 µL of DMSO was added to each well to 
dissolve the formazan. The optical densities at dual wavelengths 
(560 and 630 nm) were determined in a spectrophotometer 
(Infinite M200, Tecan, Mannedorf, Switzerland).  
Cytofluorometric Analysis of Apoptosis, Necrosis and 
Survival: freshly isolated neutrophils were resuspended in 
supplemented RPMI medium at 2 x 10
6
 cells/mL. 25 µL were 
cultured in a 96-well plate containing 200 µL of supplemented 
RPMI medium for 24 h in the absence or presence of the 
compounds as described previously.
12
 Assessment of apoptosis 
was performed by flow cytometry using annexin V-FITC and 
propidium iodide (PI). The protocol indicated by the 
manufacturer (FITC Annexin V Apoptosis Detection Kit I; BD 
Biosciences) was used as outlined previously.
13
 Cells (1 x 10
4
) 
were analyzed in a BD FACSVerse Flow Cytometer (BD 
Biosciences, San Jose, CA) and differentiated as early or viable 
apoptotic (annexin V+ and PI-), late apoptotic and/or necrotic 
(annexin V+ and PI+), and viable nonapoptotic (annexin V- and 
PI-) cells. 
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